

## MATERIALS LICENSE

Amendment No. 16

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee		In accordance with letter dated June 16, 1987	
1. South Community Hospital		3. License number 35-13127-01 is amended in its entirety to read as follows:	
2. 1001 S.W. 44th Oklahoma City, Oklahoma 73109		4. Expiration date December 31, 1991	
		5. Docket or Reference No. 030-02921	
6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	
A. Any byproduct material identified in 10 CFR 35.100	A. Any radiopharmaceutical identified in 10 CFR 35.100	A. As needed	
B. Any byproduct material identified in 10 CFR 35.200	B. Any radiopharmaceutical identified in 10 CFR 35.200	B. As needed	
C. Any byproduct material identified in 10 CFR 35.300	C. Any radiopharmaceutical identified in 10 CFR 35.300	C. As needed	
D. Any byproduct material identified in 10 CFR 35.400	D. Any brachytherapy source identified in 10 CFR 35.400	D. As needed	
E. Any byproduct material identified in 10 CFR 35.500	E. Sealed sources for diagnostic devices identified in 10 CFR 35.500	E. 2 curies per source	
F. Any byproduct material identified in 10 CFR 31.11	F. Prepackaged Kits	F. As needed	
8801250065 870716 REG 4 LIC 30 35-13127-01 PDR			
9. Authorized Use:			
A. Medical use described in 10 CFR 35.100.			
B. Medical use described in 10 CFR 35.200.			
C. Medical use described in 10 CFR 35.300.			
D. Medical use described in 10 CFR 35.400 and, for Cesium-137, calibration of licensee's survey instruments and personnel dosimeters.			
E. Medical use described in 10 CFR 35.500.			
F. <u>In vitro</u> studies.			

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License number  
35-13127-01

Docket or Reference number  
030-02921

Amendment No. 16

**CONDITIONS**

10. Location of use: 1001 S.W. 44th Street, Oklahoma City, Oklahoma.
11. Radiation Safety Officer: John D. Bush, M.D.
12. Authorized Users:
  - A. David E. Rogers, M.D., for material identified in 10 CFR 35.100, 35.200, 35.300, 35.400, and 35.500; and for in vitro studies.
  - B. John D. Bush, M.D., for material identified in 10 CFR 35.100, 35.200, 35.300, 35.400, and 35.500; and for in vitro studies.
  - C. Ralph J. Cramer, M.D., for material identified in 10 CFR 35.100, 35.200, 35.300, 35.400, and 35.500; and for in vitro studies.
  - D. Richard Cook, M.D., for material identified in 10 CFR 35.100, 35.200, and 35.500; and for in vitro studies.
  - E. Kenneth Harper, M.D., for material identified in 10 CFR 35.100, 35.200, and 35.500; and for in vitro studies.
  - F. Morris J. Wizenberg, M.D., for material identified in 10 CFR 35.400 and 35.500.
  - G. Darrell L. Speed, M.D., for material identified in 10 CFR 35.400 and 35.500.
  - H. William C. Bradford, Jr., M.D., for material identified in 10 CFR 35.100, 35.200, and 35.500; Phosphorus-32 colloidal chromic phosphate for intracavitary treatment of malignant effusions; and for in vitro studies.
  - I. Alexander P. Turner, Ph.D., for material identified in 10 CFR 35.400 for instrument calibration only.
13. This license is based on the licensee's statements and representations dated August 28, 1986, and November 5, 1986.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date JUL 16 1987

Original signed by  
JACK E. WHITTEN

By  
Nuclear Materials Licensing Section  
Region IV  
Arlington, Texas 76011

OFFICIAL RECORD COPY




UNITED STATES  
NUCLEAR REGULATORY COMMISSION  
REGION IV  
611 RYAN PLAZA DRIVE, SUITE 1000  
ARLINGTON, TEXAS 76011

03002921  
02120  
12/91

BETWEEN: William O. Miller, Chief  
License Fee Management Branch  
Office of Administration

R. J. Everett, Chief  
Material Radiation Protection Section, TPB,  
DV&TP, RIV



LICENSEE FEE TRANSMITTAL

A. REGION

1. APPLICATION ATTACHED

Applicant/Licensee:

Application Dated:

Control No.:

License No.:

South Community Hosp.  
6/16/87  
461547  
35-13127-01 (030-02921)

2. FEE ATTACHED

Amount:

Check No.:

\$120-  
008644

3. COMMENTS

Signed

Date

Laura Turley  
6/22/87

B. LICENSEE FEE MANAGEMENT BRANCH

1. Fee Category and Amount:

2. Correct Fee Paid. Application may be processed for:

Amendment ☒

Renewal ☐

License ☐

Signed


Date

S. Turley  
6/25/87



4658

June 16, 1987



U.S. Nuclear Regulatory Commission  
Region IV  
Material Radiation Protection Section  
611 Ryan Plaza Drive, Suite 1000  
Arlington, Texas 76011

RE: License No. 35-13127-01

Dear Sir:

We are requesting an amendment to Condition 11 of our Byproduct Materials License.

We would like to add Darrell L. Speed, M.D., as an authorized user under Condition 11 for Group IV byproduct materials. Supplement A, Supplement B, and a letter of evaluation are submitted for your review.

A check for \$120.00 is attached to cover the cost of this amendment. We understand the license fee category is 7.C of Part 170.31.

If you need additional information, please let us know.

Sincerely,

*Alexander P. Turner*  
Alexander P. Turner, Ph.D.  
APT:pp

cc: Joe Neely  
Harold Hart  
Beverly Spear  
John D. Bush, M.D.  
Morris J. Wizenberg, M.D.  
Darrell L. Speed, M.D.

Log	Jun. 4 <i>TL</i>
Remitter	
Check No.	008644
Amount	\$120
Fee Category	7C
Type of Fee	Amendment
Date Check	6/23/87
Date Completed	6/23/87
By:	<i>S. L. Lumb</i>

8801200073 870716  
REG4 LIC30  
35-13127-01 PDR

461547

**SUPPLEMENT A**  
**TRAINING AND EXPERIENCE**  
**PROPOSED AUTHORIZED USER OR RADIATION SAFETY OFFICER**

1. NAME OF PROPOSED AUTHORIZED USER OR RADIATION SAFETY OFFICER  Darrell Louie Speed		2. STATE OR TERRITORY IN WHICH LICENSED TO PRACTICE MEDICINE (If physician)  Oklahoma	
<b>3. CERTIFICATION</b>			
SPECIAL BOARD	CATEGORY	MONTH AND YEAR CERTIFIED	
<b>4. TRAINING RECEIVED IN BASIC RADIOISOTOPE HANDLING TECHNIQUES (To be completed by institution providing training)</b>			
FIELD OF TRAINING	LOCATION AND DATE(S) OF TRAINING	TYPE AND LENGTH OF TRAINING	
		LECTURE/LABORATORY COURSE (Hours)	FORMAL SUPERVISED OUT/LABORATORY EXPERIENCE (Hours)
RADIATION PHYSICS AND INSTRUMENTATION	Oklahoma Memorial Hospital P. O. Box 26307 Oklahoma City, Oklahoma	110	40
RADIATION PROTECTION	Same	40	12
MATHEMATICS PERTAINING TO THE USE, MEASUREMENT, AND SHIELDING OF RADIOACTIVE SOURCES	Same	25	50
RADIATION BIOLOGY	Same	36	12
<b>5. EXPERIENCE WITH RADIOACTIVE MATERIALS* (Actual use of radioisotopes or equivalent experience)</b>			
ISOTOPE	MAXIMUM AMOUNT FOR ANY SINGLE APPLICATION	WHERE EXPERIENCE WAS GAINED	DURATION OF EXPERIENCE
60 Co 198 Au 192 Ir 90 Sr  226 Ra	6230 Ci 50 mCi 260 mCi 125 mCi  90 mg	Oklahoma Memorial Hospital	July 1, 1984 to June 30, 1987
			Teletherapy Interstitial Interstitial Superficial Eye Intracavitary
*Experience with sealed radioactive sources under the supervision of qualified instructors should include:			
1. Review of initial source calibration and periodic spot-check measurements of teletherapy units.		4. Preparation of treatment plans and treatment issues for brachytherapy.	
2. Initial source calibration of sealed sources other than teletherapy sources that are used for treatment purposes.		5. Knowledge of appropriate radiation safety, quality control, and emergency procedures for handling and using sealed sources.	
3. Calibration of ion chambers and survey meters.			
6. I CERTIFY THAT THE INFORMATION PRESENTED ABOVE IS TRUE AND CORRECT TO THE BEST OF MY KNOWLEDGE AND BELIEF (Signature of program supervisor)			
TYPED OR PRINTED NAME  William J. Graham, M.D.			DATE  May 28, 1987
NAME OF INSTITUTION  Oklahoma Memorial Hospital			
MAILING ADDRESS  P. O. Box 26307			
CITY  Oklahoma City	STATE  Okla.	ZIP CODE  73126	RADIOACTIVE MATERIALS LICENSE NUMBER  35 21035-02
WARNING: 18 U.S.C. Section 1001, Act of June 25, 1948, 62 Stat. 749, makes it a criminal offense to make a willfully false statement or representation to any department or agency of the United States as to any matter within its jurisdiction.			



# SUPPLEMENT B PRECEPTOR STATEMENT

Supplement B must be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each.

## 1. APPLICANT PHYSICIAN'S NAME AND ADDRESS

FULL NAME

Darrell Louie Speed, M.D.

STREET ADDRESS

8108 N. W. 29th

CITY

Bethany

STATE

Okla

ZIP CODE

73008

## KEY TO COLUMN C PERSONAL PARTICIPATION SHOULD CONSIST OF:

1. Supervised examination of patients to determine the suitability for radioisotope therapy and recommendations on dosage to be prescribed.
2. Collaboration in calculation of radiation dose, related measurement, and modification of the originally prescribed dose as warranted by patient reaction to the radiation.
3. Followup of patients when required.
4. Study and discussion with preceptor of case histories to establish the most appropriate therapy procedures, limitations, contraindications, etc.

## 2. CLINICAL TRAINING AND EXPERIENCE OF PHYSICIAN CITED ABOVE IN USING SOURCES OR DEVICES FOR THERAPY

ISOTOPE A	TYPES OF TREATMENT B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Append additional information, if necessary) D
Co-60	COURSES OF TELETHERAPY TREATMENT	78	
OR	INTERSTITIAL	0	
Cs-137	INTRACAVITARY	0	
Ir-192 OR Au-198 SEEDS	INTERSTITIAL	7	
Ra-226	INTRACAVITARY	20	
X-RAY AND ACCELERATOR THERAPY	COURSES OF THERAPY TREATMENT	483	
Si-60	SUPERFICIAL EYE CONDITIONS	5	
OTHER	32p Intracavitary	2	

DATES AND TOTAL NUMBER OF HOURS: CLINICAL TRAINING USING SEALED SOURCES + THERAPY

July 1, 1984 to June 30, 1987, 1728 hours.

## 3. PRECEPTOR'S CERTIFICATION

NAME OF SUPERVISOR

William J. Graham, M.D.

NAME OF INSTITUTION

Oklahoma Memorial Hospital

RADIOACTIVE MATERIALS

LICENSEE NUMBER  
35-21035-02

MAILING ADDRESS

P. O. Box 26307

CITY

Oklahoma City

STATE

Okla.

ZIP CODE

73126

I CERTIFY THAT (a) THE INFORMATION PRESENTED ABOVE IS TRUE AND CORRECT TO THE BEST OF MY KNOWLEDGE AND BELIEF, AND (b) I WAS AUTHORIZED BY THE REFERENCED RADIOACTIVE MATERIALS LICENSE(S) TO PERFORM THE PROCEDURES SPECIFIED ABOVE. I FURTHER BELIEVE THAT THE APPLICANT PHYSICIAN IS COMPETENT TO PERFORM THESE PROCEDURES INDEPENDENTLY. (Signature)

*William J. Graham*

DATE

5/28/87

WARNING: 18 U.S.C. Section 1001, Act of June 25, 1948, 62 Stat. 749, makes it a criminal offense to make a willfully false statement of representation to any department or agency of the United States as to any matter within its jurisdiction.



*The*  
**University of Oklahoma**  
*Oklahoma City Campus - Health Sciences Center*

DEPARTMENT OF RADIOLOGICAL SCIENCES  
College of Medicine  
Division of Radiation Therapy

Date: June 2, 1987

To: United States Nuclear Regulatory Commission

The University of Oklahoma College of Medicine Department of Radiological Sciences Residency Program in Radiation Oncology is accredited by the Residency Review Committee for Radiology of the Accreditation Council for Medical Education. On July 1, 1984 Dr. Darrell Louie Speed entered this program. His training has included all phases of radiation physics, radiation biology, radiation protection, and clinical aspects of treatment planning, dosimetry, and patient treatment as prescribed by the Accreditation Council and the American Board of Radiology. Dr. Speed will successfully complete all of the requirements of the program on June 30, 1987 and will then be competent to independently use both teletherapy and brachytherapy sources for patient treatment.

William J. Graham, M.D.  
Associate Professor, Department of Radiology  
Director, Residency Program

8801250095 870716  
REG4 LIC30  
35-13127-01  
PDR